Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAJEVE THOMAS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1760677108
CMS profile
171309
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$115,051.57

87 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $41,177.34 21
SpringWorks Therapeutics, Inc. $26,884.41 31
E.R. Squibb & Sons, L.L.C. $16,517.43 9
ARRAY BIOPHARMA INC $15,365.67 6
Immunocore Limited $12,971.72 19
Merck Sharp & Dohme LLC $2,135.00 1

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAJEVE THOMAS

NPI 1760677108 · CMS profile ID 171309

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1760677108?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAJEVE THOMAS, NPI 1760677108, CMS profile ID 171309. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760677108?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SAJEVE THOMAS, NPI 1760677108, CMS profile ID 171309. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760677108?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SAJEVE THOMAS, NPI 1760677108, CMS profile ID 171309, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–87 of 87 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1760677108?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

87 matching records · $115,051.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 87 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–87 of 87.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SpringWorks Therapeutics, Inc. $290.9807/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808565 CMS
SpringWorks Therapeutics, Inc. $920.0006/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808563 CMS
ARRAY BIOPHARMA INC $1,080.4006/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131917717 CMS
SpringWorks Therapeutics, Inc. $1,150.0006/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808561 CMS
PFIZER INC. $4,250.0006/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131448653 CMS
SpringWorks Therapeutics, Inc. $619.4106/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808555 CMS
SpringWorks Therapeutics, Inc. $1,380.0006/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808557 CMS
SpringWorks Therapeutics, Inc. $283.4806/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808559 CMS
ARRAY BIOPHARMA INC $2,250.0006/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131920335 CMS
Merck Sharp & Dohme LLC $2,135.0006/03/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141552445 CMS
PFIZER INC. $335.8805/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131915243 CMS
ARRAY BIOPHARMA INC $5,375.0005/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131916486 CMS
PFIZER INC. $4,125.0005/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131916354 CMS
E.R. Squibb & Sons, L.L.C. $2,664.0005/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101350086 CMS
PFIZER INC. $75.0005/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131915666 CMS
PFIZER INC. $24.0005/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131919323 CMS
PFIZER INC. $5,250.0005/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131919045 CMS
PFIZER INC. $85.0904/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131915328 CMS
PFIZER INC. $153.9804/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131916921 CMS
ARRAY BIOPHARMA INC $140.2704/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131234244 CMS
SpringWorks Therapeutics, Inc. $1,150.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808553 CMS
PFIZER INC. $75.0002/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131907381 CMS
PFIZER INC. $631.7502/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131908293 CMS
SpringWorks Therapeutics, Inc. $2,070.0002/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808551 CMS
E.R. Squibb & Sons, L.L.C. $1,593.7502/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101350062 CMS
E.R. Squibb & Sons, L.L.C. $1,593.7502/20/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1155508451 CMS
PFIZER INC. $5,250.0002/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131906383 CMS
PFIZER INC. $112.7302/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131910646 CMS
SpringWorks Therapeutics, Inc. $1,150.0002/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808549 CMS
SpringWorks Therapeutics, Inc. $117.2602/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808547 CMS
ARRAY BIOPHARMA INC $770.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131991605 CMS
SpringWorks Therapeutics, Inc. $2,070.0002/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808545 CMS
E.R. Squibb & Sons, L.L.C. $1,482.0002/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101350060 CMS
E.R. Squibb & Sons, L.L.C. $1,482.0002/05/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1155508453 CMS
SpringWorks Therapeutics, Inc. $2,070.0001/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808543 CMS
SpringWorks Therapeutics, Inc. $124.6101/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808541 CMS
SpringWorks Therapeutics, Inc. $112.0001/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085808539 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $143,039.50 123
PY2020 $85,446.89 36
PY2021 $80,065.48 31
PY2022 $113,407.07 71
PY2023 $38,394.68 34
PY2024 $115,051.57 87
PY2025 $63,898.45 83

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,002.80 8
PY2025 Principal investigator $548,654.05 295
PY2024 Recipient $2,550.55 9
PY2024 Principal investigator $2,013,861.09 646
PY2023 Recipient $7,395.49 31
PY2023 Principal investigator $1,721,462.54 437
PY2022 Recipient $345.64 1
PY2022 Principal investigator $700,574.06 79
PY2021 Principal investigator $646,971.81 32
PY2020 Principal investigator $795,004.69 34
PY2019 Principal investigator $506,322.98 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

303 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $524.00 12/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 12/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 12/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 12/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 12/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 12/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.40 11/26/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 11/26/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 11/26/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 11/26/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 11/26/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 11/26/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 11/19/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 11/19/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 11/19/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 11/19/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 11/19/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 11/19/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 10/29/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 09/29/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 09/29/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.55 09/29/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.55 09/29/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.55 09/29/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 09/29/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $682.55 09/29/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/25/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/15/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/15/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 09/15/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 09/15/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 09/15/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 09/15/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 09/15/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 09/15/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134455
Recipient Regeneron Pharmaceuticals, Inc. $258.14 09/10/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184123444
Recipient Regeneron Pharmaceuticals, Inc. $104.73 08/29/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184123442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $590.00 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.00 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 08/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 08/11/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 08/11/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 08/08/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/11/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/11/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/11/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/11/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/11/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/11/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/11/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.40 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.40 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,944.04 06/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $350.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 06/18/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 06/18/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 06/18/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 06/18/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 06/18/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134171
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $524.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $569.85 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $569.85 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134237
Recipient Regeneron Pharmaceuticals, Inc. $119.77 06/06/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184123440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 06/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $590.00 06/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,574.20 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,574.20 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 05/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134137
Principal investigator 1 Iovance Biotherapeutics, Inc. $459.00 05/07/2025 Covered Recipient Teaching Hospital
Orlando Health
NCT05361174 No dispute reported 06/30/2026 1252497519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 05/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 05/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 05/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 05/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 05/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 05/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.00 05/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 05/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134111
Recipient Regeneron Pharmaceuticals, Inc. $292.81 04/29/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184123438
Recipient Regeneron Pharmaceuticals, Inc. $443.22 04/05/2025 Covered Recipient Physician A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184123434
Recipient Regeneron Pharmaceuticals, Inc. $396.99 04/05/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184123436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 04/01/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.40 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.40 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 03/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 03/25/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 03/25/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 03/25/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 03/25/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $524.00 03/25/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.40 03/25/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 03/25/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 03/25/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184134013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.40 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 03/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133997
Principal investigator 1 Immunocore Limited $1,000.00 03/14/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,743.74 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.40 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $524.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133941
Recipient Regeneron Pharmaceuticals, Inc. $148.22 02/25/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184123432
Recipient Regeneron Pharmaceuticals, Inc. $238.92 02/14/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184123430
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 02/14/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 1223268714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 02/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 02/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 02/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 02/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,250.00 02/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133881
Principal investigator 1 Immunocore Limited $500.00 02/03/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 02/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,277.55 02/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133871
Principal investigator 1 Iovance Biotherapeutics, Inc. $500.00 01/29/2025 Covered Recipient Teaching Hospital
Orlando Health
NCT05361174 No dispute reported 06/30/2026 1252497521
Principal investigator 1 Immunocore Limited $842.33 01/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146843
Principal investigator 1 Immunocore Limited $2,092.99 01/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146845
Principal investigator 1 Immunocore Limited $1,974.17 01/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146847
Principal investigator 1 Immunocore Limited $842.33 01/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146849
Principal investigator 1 Immunocore Limited $842.33 01/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146851
Principal investigator 1 Immunocore Limited $1,049.31 01/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146853
Principal investigator 1 Immunocore Limited $1,049.31 01/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146855
Principal investigator 1 Immunocore Limited $1,049.31 01/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146857
Principal investigator 1 Immunocore Limited $1,049.31 01/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $569.85 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $569.85 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $524.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $334.05 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $524.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $576.40 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,947.50 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $524.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $524.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,013.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.00 01/22/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA No dispute reported 06/30/2026 1184133863
Principal investigator 1 Adaptimmune LLC $15,336.17 01/09/2025 Covered Recipient Teaching Hospital
Orlando Health
SURPASS-1 No dispute reported 06/30/2026 1248275263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,497.43 01/09/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1184133791